22.12
+0.71(+3.32%)
Currency In USD
Address
6200 Lookout Road
Boulder, CO 80301
United States of America
Phone
720 647 8519
Sector
Healthcare
Industry
Biotechnology
Employees
62
First IPO Date
March 12, 2020
| Name | Title | Pay | Year Born |
| Mr. Samuel S. Kintz M.B.A. | Co-Founder, Chief Executive Officer, Secretary & Director | 973,800 | 1986 |
| Mr. Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | 488,500 | 1989 |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer | 709,400 | 1965 |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer | 746,400 | 1963 |
| Mr. Anish Patel Pharm.D. | Co-Founder & Chief Operating Officer | 0 | 1980 |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | 0 | 1977 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
